Tutor, pleas help me with these 2 questions with detail explanation.

3. Problem 5.21 to 5.24 from the 8th edition of the textbook Pulmonary Disease Forced expiratory volume (FEV) is an index of pulmonary function that measures the volume of air expelled after 1 second of constant effort. FEV is influenced by age, sex, and cigarette smoking. Assume that in 45- to 54-yearold nonsmoking men FEV is normally distributed with mean = 4.0 L and standard deviation = 0.5 L. In comparably aged currently smoking men FEV is nor- mally distributed, with mean = 3.5 L and standard deviation = 0.6 L. 5.21 If an FEV of less than 2.5 L is regarded as showing some functional impairment (occasional breathlessness, inability to climb stairs, etc.), then what is the probability that a currently smoking man has functional impairment? 5.22 Answer Problem 5.21 for a nonsmoking man. Some people are not functionally impaired now, but their pulmonary function usually declines with age and they even- tually will be functionally impaired. Assume that the decline in FEV over n years is normally distributed, with mean = 0.03n L and standard deviation = 0.02n L. 5.23 What is the probability that a 45-year-old man with an FEV of 4.0 L will be functionally impaired by age 75? 5.24 Answer Problem 5.23 for a 25-year-old man with an FEV of 4.0 L. 4. Problem 5.65 to 5.67 from the 8th edition of the textbook Hypertension A doctor diagnoses a patient as hypertensive and pre- scribes an antihypertensive medication. To assess the clinical status of the patient, the doctor takes n replicate blood-pressure measurements before the patient starts the drug (baseline) and n replicate bloodpressure measure ments 4 weeks after starting the drug (followup). She uses the average of the n replicates at baseline minus the average of the n replicates at follow-up to assess the clini- cal status of the patient. She knows, from previous clinical experience with the drug, that the mean diastolic blood pressure (DBP) change over a 4week period over a large number of patients after starting the drug is 5.0 mm Hg with variance 33, where n is the number of replicate measures obtained at both baseline and follow-up. 5.65 If we assume the change in mean DBP is normally distributed, then what is the probability that a subject will decline by at least 5 mm Hg if 1 replicate measure is obtained at baseline and followup? 5.66 The physician also knows that if a patient is untreated (or does not take the prescribed medication), then the mean DBP over 4 weeks will decline by 2 mm Hg with variance 33. What is the probability that an untreated subject will decline by at least 5 mm Hg if 1 replicate measure is obtained at both baseline and follow-up? 5.67 Suppose the physician is not sure whether the patient is actually taking the prescribed medication. She wants to take enough replicate measurements at baseline and follow-up so that the probability in Problem 5.65 is at least five times the probability in Problem 5.66. How many repli cate measurements should she take